Share on StockTwits

Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Floyd F. Petersen bought 3,200 shares of Amphastar Pharmaceuticals stock on the open market in a transaction dated Friday, August 15th. The stock was purchased at an average cost of $10.35 per share, with a total value of $33,120.00. Following the completion of the purchase, the director now directly owns 41,612 shares in the company, valued at approximately $430,684. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Amphastar Pharmaceuticals from $14.00 to $15.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $17.00 to $18.00 in a research note on Wednesday, August 6th. Finally, analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down 0.10% on Tuesday, hitting $10.01. 101,211 shares of the company’s stock traded hands. Amphastar Pharmaceuticals has a one year low of $6.67 and a one year high of $11.07. The stock’s 50-day moving average is $9.40 and its 200-day moving average is $9.44. The company’s market cap is $434.5 million.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Tuesday, August 12th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.13. On average, analysts predict that Amphastar Pharmaceuticals will post $-0.22 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.